Cost effectiveness

Value in the Cath Lab: Contemporary Use of GP IIb/IIIa Inhibitors in the Treatment of ACS at the Mayo Clinic Heath System

07/09/2016

Cath Lab Digest talks with Eric H. Yang, MD,
Director, Cardiac Catheterization Laboratory and Interventional Cardiology,
Associate Professor of Medicine, Mayo Clinic, Scottsdale, Arizona.

Cath Lab Digest talks with Eric H. Ya...

In terms of choosing which GP IIb/IIIa inhibitor to use, what historically has just been a two-person game, is now a three-person game that includes abciximab, eptifibatide, and tirofiban.

In terms of choosing which GP...

07/09/2016

Cath Lab Digest

Daratumumab More Cost Effective for Multiple Myeloma Treatment

06/13/2016

JCP Editors

Daratumumab may be the most cost-effective treatment option for patients with multiple myeloma (MM) compared with other novel therapies, according to a poster presented at the 2016 American Society of Clinical...

...

06/13/2016

Journal of Clinical Pathways

Research Reports

Cost-Effectiveness of Afatinib Versus Erlotinib in the First-line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 19 Deletion Mutations

05/06/2016

Jonathan Graham, BS

Stephanie Earnshaw, PhD

Jonathan Lim, BS, MS, MSc

Rakesh Luthra, MS

Rohit Borker, PhD

Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...

...

05/06/2016

Journal of Clinical Pathways

Applying a Cost-Effectiveness Methodology to Angina

01/13/2015

Cath Lab Digest talks with David J. Cohen, MD, MSc, Professor of Medicine,
University of Missouri-Kansas City, and Director of Cardiovascular Research,
Saint Luke’s Mid America Heart Institute, Kansas City, Missouri.

Cath Lab Digest talks with David J. C...

There are many causes of angina, but what is very clear from research that has been done over the last several decades is that angina has an important impact on patients’ quality of life. It limits the activities they do, it limits their...

There are many causes of angina,...

01/13/2015

Cath Lab Digest

Clinical and Economic Advantages of the iFR Modality for Physiologic Assessment

12/05/2014

Bruce A. Samuels, MD, Division of Cardiology, Cedars-Sinai Medical Center; Assistant Professor of Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California

Bruce A. Samuels, MD, Division of Car...

Approved by the FDA in March 2014, iFR is a diagnostic tool used to assess whether a stenosis is causing a limitation of blood flow in coronary arteries with subsequent ischemia. This tool preserves the advantages of physiology-based...

Approved by the FDA in March...

12/05/2014

Cath Lab Digest

Original Research

Trends in the Incidence of Carotid Body Tumors in the United States From 1998 to 2011

12/03/2014

Anahita Dua, MD¹; Tanner C. Spees, MD¹;Francisco C Hernandez, MD²; Anthony A. Igbadumhe, MD³; Mohammed Algodi, MD⁴; Sapan S. Desai, MD⁵

¹Medical College of Wisconsin, Milwaukee; ²University of Carabobo School of Medicine, Valencia, Venezuela; ³Ambrose Alli University College of Medicine, Ekpoma, Nigeria; ⁴Montefiore Medical Center, Bronx, New York;⁵Duke University Medical Center, Durham, North Carolina

Anahita Dua, MD1; Tanner C. Spees, MD...

The authors conducted a retrospective analysis of hospital discharge data to determine national trends in carotid body tumors in the United States by year, incidence, patient demographics, and hospital covariates.

The authors conducted a...

12/03/2014

Vascular Disease Management